These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

319 related items for PubMed ID: 36176438

  • 21. Effects of Glucagon-Like Peptide-1 Receptor Agonists, Sodium-Glucose Cotransporter-2 Inhibitors, and Their Combination on Endothelial Glycocalyx, Arterial Function, and Myocardial Work Index in Patients With Type 2 Diabetes Mellitus After 12-Month Treatment.
    Ikonomidis I, Pavlidis G, Thymis J, Birba D, Kalogeris A, Kousathana F, Kountouri A, Balampanis K, Parissis J, Andreadou I, Katogiannis K, Dimitriadis G, Bamias A, Iliodromitis E, Lambadiari V.
    J Am Heart Assoc; 2020 May 05; 9(9):e015716. PubMed ID: 32326806
    [Abstract] [Full Text] [Related]

  • 22. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study.
    Kim YG, Han SJ, Kim DJ, Lee KW, Kim HJ.
    Cardiovasc Diabetol; 2018 Jun 23; 17(1):91. PubMed ID: 29935543
    [Abstract] [Full Text] [Related]

  • 23. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study.
    Baviera M, Foresta A, Colacioppo P, Macaluso G, Roncaglioni MC, Tettamanti M, Fortino I, Genovese S, Caruso I, Giorgino F.
    Cardiovasc Diabetol; 2022 Aug 24; 21(1):162. PubMed ID: 35999556
    [Abstract] [Full Text] [Related]

  • 24. SGLT2 Inhibitors and the Risk of Acute Kidney Injury in Older Adults With Type 2 Diabetes.
    Zhuo M, Paik JM, Wexler DJ, Bonventre JV, Kim SC, Patorno E.
    Am J Kidney Dis; 2022 Jun 24; 79(6):858-867.e1. PubMed ID: 34762974
    [Abstract] [Full Text] [Related]

  • 25. Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes.
    Nørgaard CH, Starkopf L, Gerds TA, Vestergaard P, Bonde AN, Fosbøl E, Køber L, Wong ND, Torp-Pedersen C, Lee CJ.
    Eur Heart J Cardiovasc Pharmacother; 2022 Sep 03; 8(6):549-556. PubMed ID: 34215881
    [Abstract] [Full Text] [Related]

  • 26. Do GLP-1RAs and SGLT-2is reduce cardiovascular events in women with type 2 diabetes? A systematic review and meta-analysis.
    Mishriky BM, Okunrintemi V, Jain S, Sewell KA, Powell JR, Cummings DM.
    Diabetes Metab; 2021 Feb 03; 47(1):101160. PubMed ID: 32439471
    [Abstract] [Full Text] [Related]

  • 27. Dipeptidyl Peptidase-4 Inhibitors, Glucagon-like Peptide-1 Receptor Agonists, and Sodium-Glucose Cotransporter-2 Inhibitors and COVID-19 Outcomes.
    Foresta A, Ojeda-Fernandez L, Macaluso G, Roncaglioni MC, Tettamanti M, Fortino I, Leoni O, Genovese S, Baviera M.
    Clin Ther; 2023 Apr 03; 45(4):e115-e126. PubMed ID: 36933975
    [Abstract] [Full Text] [Related]

  • 28. Association of glucagon-like peptide-1 receptor agonists with suicidal ideation and self-injury in individuals with diabetes and obesity: a propensity-weighted, population-based cohort study.
    Hurtado I, Robles C, Peiró S, García-Sempere A, Sanfélix-Gimeno G.
    Diabetologia; 2024 Nov 03; 67(11):2471-2480. PubMed ID: 39103719
    [Abstract] [Full Text] [Related]

  • 29. The Effect of Glucagon-Like Peptide-1 Receptor Agonists on Diabetic Retinopathy at a Tertiary Care Center.
    Joo JH, Sharma N, Shaia J, Wu AK, Skugor M, Singh RP, Rachitskaya AV.
    Ophthalmol Sci; 2024 Nov 03; 4(6):100547. PubMed ID: 39139548
    [Abstract] [Full Text] [Related]

  • 30. SGLT-2 inhibitors and the risk of hospitalization for community-acquired pneumonia: A population-based cohort study.
    Brunetti VC, Reynier P, Azoulay L, Yu OHY, Ernst P, Platt RW, Filion KB.
    Pharmacoepidemiol Drug Saf; 2021 Jun 03; 30(6):740-748. PubMed ID: 33428309
    [Abstract] [Full Text] [Related]

  • 31. Effects of new hypoglycemic drugs on cardiac remodeling: a systematic review and network meta-analysis.
    Huang YL, Xu XZ, Liu J, Wang PY, Wang XL, Feng HL, Liu CJ, Han X.
    BMC Cardiovasc Disord; 2023 Jun 09; 23(1):293. PubMed ID: 37296380
    [Abstract] [Full Text] [Related]

  • 32. Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.
    Dong YH, Chang CH, Lin JW, Yang WS, Wu LC, Toh S.
    Diabetes Obes Metab; 2022 Aug 09; 24(8):1623-1637. PubMed ID: 35491533
    [Abstract] [Full Text] [Related]

  • 33. Two years with GIOIA 'Effects of gliflozins and gliptins on markers of cardiovascular damage in type 2 diabetes': A prospective, multicentre, quasi-experimental study on sodium-glucose cotransporter 2 and dipeptidyl peptidase-4 inhibitors in diabetes clinical practice.
    Longo M, Caruso P, Scappaticcio L, Maiorino MI, Bellastella G, Capuano A, Esposito K, Giugliano D.
    Diabetes Obes Metab; 2024 Apr 09; 26(4):1492-1501. PubMed ID: 38234208
    [Abstract] [Full Text] [Related]

  • 34. Comparative Cardiovascular Effectiveness and Safety of SGLT-2 Inhibitors, GLP-1 Receptor Agonists, and DPP-4 Inhibitors According to Frailty in Type 2 Diabetes.
    Kutz A, Kim DH, Wexler DJ, Liu J, Schneeweiss S, Glynn RJ, Patorno E.
    Diabetes Care; 2023 Nov 01; 46(11):2004-2014. PubMed ID: 37677118
    [Abstract] [Full Text] [Related]

  • 35. Cardiovascular effectiveness of glucagon-like peptide 1 receptor agonists versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes: A meta-analysis based on propensity score-matched studies.
    Xu L, Zheng XQ, Liao XX.
    Prim Care Diabetes; 2022 Feb 01; 16(1):207-210. PubMed ID: 34953749
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Glucagon-like-1 receptor agonists and sodium/glucose cotransporter-2 inhibitors combination-are we exploiting their full potential in a real life setting?
    Berkovic MC, Bilic-Curcic I, Bozek T, Mahecic DH, Majanovic SK, Canecki-Varzic S, Andric J, Marusic S, Mrzljak A.
    World J Diabetes; 2020 Nov 15; 11(11):540-552. PubMed ID: 33269065
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes.
    Riley DR, Essa H, Austin P, Preston F, Kargbo I, Ibarburu GH, Ghuman R, Cuthbertson DJ, Lip GYH, Alam U.
    Diabetes Obes Metab; 2023 Oct 15; 25(10):2897-2909. PubMed ID: 37385958
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.